Blueprint Medicines gets more ducks in a row before CEO transition; Paul Stoffels has his work cut out for him at Gilead’s crumbling partner
→ When Jeff Albers announced he would no longer be CEO of Blueprint Medicines, the leadership carousel at the Aykakit maker had yet to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
